Floatz logo

NEOSTIGMINE

Neuromuscular Blockade

Merck Sharp & Dohme LLCSmall moleculePhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neuromuscular Blockade cohort.

Asset / SponsorPhaseRating
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4A
ANDROSTANE-3,17-DIOL, 16-(1-METHYL-1-PIPERIDINIUMYL)-2-(1-PIPERIDINYL)-, DIACETATE (ESTER), (2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)-
Merck Sharp & Dohme LLC
Phase 4BB
Glycopyrrolate
Merck Sharp & Dohme LLC
Phase 4BB
Rocuronium
Merck Sharp & Dohme LLC
Phase 4BB
CISATRACURIUM ION
Merck Sharp & Dohme LLC
Phase 4BB
SUXAMETHONIUM
Merck Sharp & Dohme LLC
Phase 4BB

Same molecule, other indications

NEOSTIGMINE is also rated in:

respiratory system disorderDormant
BB
Indicative ·
69 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
69 / 100
View asset →
Surgical ConditionsDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →